Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical

Pfizer Licenses Athersys' Stem Cell Technology For IBD Drug Development

This article was originally published in The Pink Sheet Daily

  • News

Executive Summary

Following the deal news, Athersys' stock price soared during same-day trading.

You may also be interested in...



Athersys Sees Efficacy Sign In MultiStem Phase I Safety Study In Heart Attack

Heart attack patients treated with Athersys' adult stem cell product MultiStem during a Phase I safety study showed improvement in cardiac function, a surprise early efficacy signal that has the company headed into Phase II studies with a spring in its step

Athersys Sees Efficacy Sign In MultiStem Phase I Safety Study In Heart Attack

Heart attack patients treated with Athersys' adult stem cell product MultiStem during a Phase I safety study showed improvement in cardiac function, a surprise early efficacy signal that has the company headed into Phase II studies with a spring in its step

Athersys Gets An Efficacy Signal In Phase I Safety Study Of MultiStem In Heart Attack

Patients in a Phase I study of the adult stem cell product showed encouraging improvement in cardiac function, a surprise efficacy signal in addition to a clean safety profile.

Table

View full table

Topics

Tags:
BioPharmaceutical
Latest Headlines

EU Sets New Date For Publication Of Delayed Pharma Revision Proposals

High Ambitions For EU DARWIN Platform After Delivery Of First RWE Studies

Two Firsts For Keytruda As NICE Says Yes To English Funding For Advanced Cervical Cancer

Shared Savings Legislation Could Increase Medicare Biosimilar Access

See All
UsernamePublicRestriction

Register

PS068911

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By